Psychedelics as a therapy
Did you know that psychedelics acceptance is just around the corner? Robust and durable beneficial mind-altering properties of single or few-doses psilocybin can be used respectfully by carefully selected young and old individuals.
Let's be clear. Some botanicals including cannabis are currently still listed on Schedule 1 of the United Nations Convention on Psychotropic Substances (1971). Scheduled substances may or may not lack therapeutic effects or may have a high potential for abuse/dependence, and may cause serious adverse effects. Psilocybe mushrooms, on the other hand, are not scheduled under the UN Convention, but many countries introduced specific laws to control them, often leading to criminal charges. However, that is only the snapshot of 50 years old scientific knowledge and political will.
Nowadays, a large body of new reliable scientific proof exists and may soon allow the substance to be re-scheduled since its risk does not correspond with the specific schedule list.
Right to science, the Right to enjoy the highest attainable standard of physical and mental health, and the Right to enjoy the benefits of scientific progress and its applications, are essential components of human rights.
Psilocybin compounds can be safely administered in controlled settings, and several therapeutic applications exist. Many patients could reap enormous benefits from the treatment with these substances administered under medical supervision. Countries like Canada have already approved compassionate medical use with these plants and fungi.
The healing power of psychedelics
Science is one step closer to reverse the damage of chronic stress
In-depth analysis of more than 75 clinical trials of psychedelic therapies being conducted as of today estimated global potential for psychedelic-based therapies as over 200 bn USD. With over 300 mn people affected by depression only across the world. Global pandemic causing a significant surge in the number of individuals affected by a mood disorder.
The potential psychedelic market is hugely lucrative.
Studies conducted by renowned medical institutions demonstrated 60–80% remission rates for depression. The clinical studies in animal models measured objective structural and functional changes in the psilocybin-treated brain. Combined with reduced risk of dependence and low toxicity, psychedelic-based therapies may become a holy grail of psychotherapy in the nearest future. Given increasing evidence of the therapeutic potential, the market is expected to develop significantly in the next decade. While West and Big Pharma have just started medicalizing psychedelics, traditional indigenous practices have a long history of validating the benefit and use.
“The available evidence suggests that these drugs (botanicals) will be incorporated in health systems worldwide in the following years,” recently concluded a team of researchers from the National Institute of Science and Technology in Brasil. The team reflects the global medical community won’t avoid incorporating psychedelics into Western societies both at the medical and social levels, so only progressive and regulating-oriented approaches (rather than repressive and persecution-oriented) will benefit the community.
Anna Deveaux, M.Sc. is a learner, writer, biotech investor who is interested in research translation, drug development, genetics.